Blog
RSS FeedPosted by Michael Wonder on 15 Jan 2019
Health Canada approves Xtandi (enzalutamide) - the first and only oral treatment for men with non-metastatic and metastatic castration-resistant prostate cancer
14 January 2019 - Astellas today announced that Health Canada approved an expanded indication for enzalutamide, an androgen receptor inhibitor for ...
Posted by Michael Wonder on 17 Dec 2018
Health Canada approves Darzalex (daratumumab) for newly diagnosed patients with multiple myeloma who are transplant ineligible
17 December 2018 - Darzalex combination therapy significantly reduced the risk of disease progression or death compared to a preferred regimen ...
Posted by Michael Wonder on 06 Dec 2018
Alberta boy with thyroid cancer runs, plays after taking U.S. approved drug
5 December 2018 - Health Canada is considering approving the oral treatment, larotrectinib. ...
Posted by Michael Wonder on 15 Nov 2018
Inclusion of data on treatment discontinuation in the Tasigna product monograph approved by Health Canada for CML patients who achieve a sustained molecular response
13 November 2018 - Approval is based on two studies showing more than half of patients remained in remission after stopping ...
Posted by Michael Wonder on 12 Nov 2018
Oversight gap at private infusion clinics poses health risk, Ontario documents say
12 November 2018 - The lack of formal oversight at private clinics where medications are administered intravenously could pose risks ...
Posted by Michael Wonder on 02 Nov 2018
Servier receives Health Canada approval of Folotyn for the treatment of relapsed or refractory peripheral T-cell lymphoma
1 November 2018 - Servier Canada announced that Health Canada granted a Notice of Compliance with conditions for Folotyn (pralatrexate) for ...
Posted by Michael Wonder on 01 Nov 2018
Novartis receives Health Canada approval for the combination therapy of Tafinlar (dabrafenib) plus Mekinist (trametinib) for adjuvant treatment of patients with BRAF V600 mutation melanoma
1 November 2018 - First approval in Canada of an adjuvant treatment for melanoma (BRAF V600 mutated). ...
Posted by Michael Wonder on 26 Sep 2018
AbbVie receives approval from Health Canada for the combination of Venclexta with rituximab as a treatment for patients with chronic lymphocytic leukaemia
25 September 2018 - In the MURANO Phase 3 clinical trial, the Venclexta (venetoclax) plus rituximab combination showed a significant improvement ...
Posted by Michael Wonder on 20 Sep 2018
Exelixis’ partner Ipsen announces Health Canada’s approval of Cabometyx (cabozantinib) tablets for the treatment of adults with previously treated advanced renal cell carcinoma
19 September 2018 - Approval based on the improvement in overall survival, progression-free survival and objective response rate for CABOMETYX versus ...
Posted by Michael Wonder on 15 Sep 2018
Herceptin (trastuzumab) subcutaneous formulation approved in Canada for the treatment of HER2-positive breast cancer
13 September 2018 - Subcutaneous formulation takes two to five minutes to administer, rather than up to 90 minutes with the ...
Posted by Michael Wonder on 07 Sep 2018
Novartis receives Health Canada approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel)
6 September 2018 - Novartis is working with qualified treatment centres to prepare for the delivery of this treatment for relapsed/refractory ...
Posted by Michael Wonder on 05 Sep 2018
Health Canada approves Perjeta (pertuzumab) for the treatment of HER2 positive early breast cancer after surgery
4 September 2018 - New treatment option can significantly reduce risk of disease recurrence or death, preventing breast cancer from returning ...
Posted by Michael Wonder on 31 Jul 2018
New treatment option for Canadians with metastatic lung cancer
30 July 2018 - Takeda Canada has received Notice of Compliance with conditions approval from Health Canada for Alunbrig (brigatinib) indicated ...
Posted by Michael Wonder on 13 Jul 2018
Health Canada approves Tagrisso (osimertinib) as first-line treatment for EGFR-mutated non-small cell lung cancer
12 July 2018 - Pivotal FLAURA study demonstrated 18.9 months median progression-free survival for patients receiving Tagrisso versus 10.2 months compared ...
Posted by Michael Wonder on 10 Jul 2018
Health Canada approves Gazyva for previously untreated advanced follicular lymphoma
9 July 2018 - Gazyva is the first anti-CD20 treatment in 15 years for the most common subtype of indolent lymphoma. ...